Immuneering Co. (NASDAQ:IMRX) Receives Average Rating of "Hold" from Analysts

Shares of Immuneering Co. (NASDAQ:IMRX - Get Free Report) have received an average rating of "Hold" from the eight analysts that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $12.20.

A number of equities research analysts have recently commented on IMRX shares. Chardan Capital reiterated a "buy" rating and set a $13.00 price objective on shares of Immuneering in a research report on Wednesday, January 8th. Morgan Stanley lowered Immuneering from an "equal weight" rating to an "underweight" rating in a research report on Friday, December 13th. Finally, Needham & Company LLC restated a "buy" rating and set a $12.00 price objective on shares of Immuneering in a report on Thursday.

Institutional Investors Weigh In On Immuneering

Several hedge funds have recently bought and sold shares of the business. HighTower Advisors LLC increased its holdings in shares of Immuneering by 21.4% in the 3rd quarter. HighTower Advisors LLC now owns 53,360 shares of the company's stock valued at $132,000 after purchasing an additional 9,400 shares during the period. Vontobel Holding Ltd. acquired a new position in Immuneering in the 3rd quarter valued at approximately $25,000. Corsair Capital Management L.P. purchased a new stake in Immuneering in the 3rd quarter worth approximately $25,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Immuneering during the 2nd quarter valued at $44,000. Finally, Tidemark LLC purchased a new position in shares of Immuneering during the 3rd quarter valued at $129,000. 67.65% of the stock is owned by hedge funds and other institutional investors.

Immuneering Trading Up 4.2 %

IMRX stock traded up $0.08 on Monday, hitting $1.99. 747,997 shares of the company's stock traded hands, compared to its average volume of 4,128,234. The stock has a market cap of $61.79 million, a price-to-earnings ratio of -1.01 and a beta of -0.36. Immuneering has a 1-year low of $1.00 and a 1-year high of $7.68. The stock has a fifty day moving average of $2.05 and a 200-day moving average of $1.87.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.